{"id":477996,"date":"2024-01-05T21:52:43","date_gmt":"2024-01-06T02:52:43","guid":{"rendered":"https:\/\/platohealth.ai\/jan-5-quick-takes-metagenomi-arrivent-file-for-ipo\/"},"modified":"2024-01-06T06:41:47","modified_gmt":"2024-01-06T11:41:47","slug":"jan-5-quick-takes-metagenomi-arrivent-file-for-ipo","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/jan-5-quick-takes-metagenomi-arrivent-file-for-ipo\/","title":{"rendered":"Jan. 5 Quick Takes:\u00a0Metagenomi, ArriVent file for IPO","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"

ARTICLE | Finance<\/p>\n

\n
\n
\n

Plus: Immunic eyes $240M private placement and updates from Applied Therapeutics and Novartis  <\/h2>\n

\n By BioCentury Staff<\/span>\n<\/p>\n

January 6, 2024 2:52 AM UTC<\/p>\n<\/div>\n<\/div>\n<\/div>\n

<\/span><\/span><\/div>\n

Two more biotechs have filed to go public ahead of next week\u2019s J.P. Morgan Healthcare Conference, marking the second and third companies of the year to aim for a NASDAQ listing: Metagenomi Inc.<\/a>, which is systematizing the search for new gene editing tools<\/a>, and ArriVent Biopharma Inc.<\/a>, which is sourcing innovative products<\/a> from China and developing them globally. <\/span><\/p>\n

The largest shareholders of Emeryville, Calif.-based Metagenomi include Bayer HealthCare LLC, Humboldt Fund, ModernaTX Inc., Sake Holdings, Sozo Ventures and RA Capital; its offering is being underwritten by J.P. Morgan, Jefferies, TD Cowen, Wells Fargo Securities, BMO Capital Markets and Chardan. <\/span>…<\/p>\n